Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone,olanzapine,quetiapine,ziprasidone,and aripiprazole
Restricted accessResearch articleFirst published online May, 2022
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone,olanzapine,quetiapine,ziprasidone,and aripiprazole
Pediatric bipolar disorder (BP) is frequently comorbid with conduct disorder (CD) and its presence adds to the morbidity of BP. While there are no known pharmacological treatments for CD, pediatric BP is responsive to treatment with medications initially indicated for the treatment of psychosis, several of which have Food and Drug Administration (FDA) approval for the treatment of pediatric mania.
Aims:
The main aim of this secondary analysis was to examine whether pediatric BP comorbid with CD responds similarly to treatment with such selected medications. Considering the well-documented morbidity of CD, this finding could have important clinical and public health significance.
Methods:
We conducted a secondary analysis of six prospective 8-week open-label trials of selected medications (risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) using identical methodology in youth with BP with and without comorbid CD. Results: Of 165 youths with BP, 54% (N = 89) met criteria for comorbid CD. The antimanic effects observed did not significantly differ between BP youths with and without comorbid CD, as measured either by a reduction in Young Mania Rating Scale (YMRS) ⩾ 30% or Clinical Global Impression (CGI)-Improvement ⩽ 2 (p = 0.23), or by the more stringent definition of a reduction in YMRS ⩾ 50% (p = 0.61).
Conclusion:
Pediatric BP can be effectively treated with the abovementioned medications in the context of comorbid CD. Based on previous research showing that remission of BP is associated with remission of CD, if confirmed, these findings raise the possibility that antimanic treatment of youth with BP comorbid with CD could have secondary benefits in mitigating the morbidity associated with CD. This is a pilot scale finding, the results of which are promising and should be confirmed by larger and long-term follow-up studies.
AmanMGDe SmedtGDerivanA, et al. (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. The American Journal of Psychiatry159(8): 1337–1346.
2.
BarnesTR (1989) A rating scale for drug-induced akathisia. The British Journal of Psychiatry154: 672–676.
3.
BarrattES (1993) The use of anticonvulsants in aggression and violence. Psychopharmacology Bulletin29(1): 75–81.
4.
BiedermanJFaraoneSHatchM, et al. (1997) Conduct disorder with and without mania in a referred sample of ADHD children. Journal of Affective Disorders44(2–3): 177–188.
5.
BiedermanJFaraoneSVChuMP, et al. (1999) Further evidence of a bidirectional overlap between juvenile mania and conduct disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry38(4): 468–476.
6.
BiedermanJFitzgeraldMWoodworthKY, et al. (2018) Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. Journal of Affective Disorders238: 244–249.
7.
BiedermanJMickEFaraoneSV, et al. (2006) Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clinical Therapeutics28(5): 794–800.
8.
BiedermanJMickEHammernessP, et al. (2005) Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biological Psychiatry58(7): 589–594.
9.
BiedermanJMickESpencerT, et al. (2007a) A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disorders9(8): 888–894.
10.
BiedermanJMickESpencerT, et al. (2007b) An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectrums12(9): 683–689.
11.
BiedermanJMickEWozniakJ, et al. (2003) Can a subtype of conduct disorder linked to bipolar disorder be identified? Integration of findings from the Massachusetts General Hospital Pediatric Psychopharmacology Research Program. Biological Psychiatry53(11): 952–960.
12.
BiedermanJPettyCRDolanC, et al. (2008) The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: Findings from a controlled 10-year prospective longitudinal follow-up study. Psychological Medicine38(7): 1027–1036.
13.
CampbellMAdamsPBSmallAM, et al. (1995) Lithium in hospitalized aggressive children with conduct disorder: A double-blind and placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry34(4): 445–453. Erratum in: Journal of the American Academy of Child and Adolescent Psychiatry 1995; 34(5): 694.
14.
CampbellMGonzalezNMSilvaRR (1992) The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatric Clinics of North America15(1): 69–85.
15.
ChingHPringsheimT (2012) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews5: CD009043.
16.
ConnersCKKramerRRothschildGH, et al. (1971) Treatment of young delinquent boys with diphenylhydantoin sodium and methyphenidate. A controlled comparison. Archives of General Psychiatry24(2): 156–160.
17.
DelBelloMPKowatchRAAdlerCM, et al. (2006) A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry45(3): 305–313.
18.
DoyleAEFaraoneS (2002) Familial links between ADHD, conduct disorder and bipolar disorder. Current Psychiatry Reports4(2): 146–152.
19.
DuPaulGJPowerTJAnastopoulosA, et al. (1998) The ADHD Rating Scale-IV Checklist, Norms and Clinical Interpretation. New York: Guilford Press.
20.
EmslieGJRushAJWeinbergWA, et al. (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry54(11): 1031–1037.
21.
EndicottJSpitzerRLFleissJL, et al. (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry33(6): 766–771.
22.
FindlingRLNyilasMForbesRA, et al. (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry70(10): 1441–1451.
23.
FindlingRLShortEJMcNamaraNK, et al. (2007) Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry46: 1445.
24.
GellerBLubyJ (1997) Child and adolescent bipolar disorder: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry36: 1168–1176.
25.
GhaeliPNikvarzNAlaghband-RadJ, et al. (2014) Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: An open label study. Indian Journal of Psychological Medicine36(1): 66–70.
26.
GraciousBLYoungstromEAFindlingRL, et al. (2002) Discriminative validity of a parent version of the Young Mania Rating Scale. Journal of the American Academy of Child and Adolescent Psychiatry41(11): 1350–1359.
27.
HaasMDelbelloMPPandinaG, et al. (2009) Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disorders11(7): 687–700.
28.
InadaTMatsudaGKitaoY, et al. (1996) Barnes Akathisia Scale: Usefulness of standardized videotape method in evaluation of the reliability and in training raters. International Journal of Methods in Psychiatric Research6: 49–52.
29.
JerrellJMMcIntyreRSParkYM (2014) Correlates of incident bipolar disorder in children and adolescents diagnosed with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry75(11): e1278–e1283.
30.
JoshiGWilensT (2009) Comorbidity in pediatric bipolar disorder. Child and Adolescent Psychiatric Clinics of North America18(2): 291–319, vii–viii.
31.
JoshiGBiedermanJWozniakJ, et al. (2012) Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. CNS Neuroscience & Therapeutics18(1): 28–33.
32.
KovacsMPollockM (1995) Bipolar disorder and comorbid conduct disorder in childhood and adolescence. Journal of the American Academy of Child and Adolescent Psychiatry34(6): 715–723.
33.
KumarATrescherWBylerD (2016) Tourette syndrome and comorbid neuropsychiatric conditions. Current Developmental Disorders Reports3(4): 217–221.
34.
KutcherSPMartonPKorenblumM (1989) Relationship between psychiatric illness and conduct disorder in adolescents. Canadian Journal of Psychiatry34(6): 526–529.
35.
LacharDBailleySERhoadesHM, et al. (2001) New subscales for an anchored version of the brief psychiatric rating scale: Construction, reliability, and validity in acute psychiatric admissions. Psychological Assessment13: 384–395.
36.
LewinsohnPKleinDSeeleyJ (1995) Bipolar disorders in a community sample of older adolescents: Prevalence, phenomenology, comorbidity, and course. Journal of the American Academy of Child and Adolescent Psychiatry34(4): 454–463.
37.
McElroySL (2004) Diagnosing and treating comorbid (complicated) bipolar disorder. Journal of Clinical Psychiatry65(Suppl. 15): 35–44.
38.
McGuireJFArnoldEParkJM, et al. (2015) Living with tics: Reduced impairment and improved quality of life for youth with chronic tic disorders. Psychiatry Research225(3): 571–579.
39.
MasiGMiloneAManfrediA, et al. (2008) Comorbidity of conduct disorder and bipolar disorder in clinically referred children and adolescents. Journal of Child and Adolescent Psychopharmacology18(3): 271–279.
40.
National Institute of Mental Health (1985) CGI (Clinical Global Impression) Scale—NIMH. Psychopharmacology Bulletin21(8): 839–844.
41.
OrvaschelH (1994) Schedule for Affective Disorders and Schizophrenia for School-Age Children Epidemiologic Version. Fort Lauderdale, FL: Center for Psychological Studies, Nova Southeastern University.
42.
OrvaschelHPuig-AntichJ (1987) Schedule for Affective Disorders and Schizophrenia for School-Age Children: Epidemiologic Version. Fort Lauderdale, FL: Nova University.
43.
PloubidisGBBattyGDPatalayP, et al. (2021) Association of early-life mental health with biomarkers in midlife and premature mortality: Evidence from the 1958 British Birth Cohort. JAMA Psychiatry78(1): 38–46.
44.
PringsheimTPanagiotopoulosCDavidsonJ, et al. CAMESA guideline group. (2011) Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth [published correction appears in J Can Acad Child Adolesc Psychiatry. 2011 August;20(3):1–2.]. J Can Acad Child Adolesc Psychiatry20(3): 218–233.
45.
RapoportJL (1985) DSM-III-R and pediatric psychopharmacology. Psychopharmacology Bulletin21(4): 803–806.
46.
SchefferREKowatchRACarmodyT, et al. (2005) Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry162: 58.
47.
SheardMH (1975) Lithium in the treatment of aggression. Journal of Nervous and Mental Disorders160(2-1): 108–118.
48.
SimpsonGMAngusJW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum212: 11–19.
49.
TohenMKryzhanovskayaLCarlsonG, et al. (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. The American Journal of Psychiatry164(10): 1547–1556.
50.
TramontinaSZeniCPKetzerCR, et al. (2009) Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: A pilot randomized clinical trial. Journal of Clinical Psychiatry70: 756–764.
51.
ViktorinARydénEThaseME, et al. (2017) The risk of treatment-emergent mania with methylphenidate in bipolar disorder. 174(4), 341–348.
52.
WilensTEBiedermanJMartelonM, et al. (2016) Further evidence for smoking and substance use disorders in youth with bipolar disorder and comorbid conduct disorder. Journal of Clinical Psychiatry77(10): 1420–1427.
53.
WozniakJMickEWaxmonskyJ, et al. (2009) Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology19(5): 539–545.
54.
YoungRCBiggsJTZieglerVE, et al. (1978) A rating scale for mania: Reliability, validity and sensitivity. The British Journal of Psychiatry133: 429–435.
55.
YoungstromEADanielsonCKFindlingRL, et al. (2002) Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years. Journal of Clinical Child and Adolescent Psychology31(4): 567–572.
